5
Jan
2021
The Vaccine Rollout Could Prompt Real Reform to the US Health System
When I received the COVID vaccine on Dec 24, it was the end of a tense, frustrating two-week period. Thousands of healthcare workers like me — doctors, nurses, physician assistants and more — at the Mass General Brigham health system were eager to get vaccinated, and antsy about whether we’d get the shot as soon as it was available. The... Read More
17
Dec
2020
Round 2: What’s Changed and What Hasn’t in Caring for Outpatients with COVID-19
When one of my COVID patients called my cell phone a few weeks ago, my stomach dropped. “I feel worse,” she stammered. “I’m having more trouble catching my breath.” It was late morning on a Sunday. I was planning to take my son to the park, but after hearing those words, I knew this was not going to be a... Read More
11
Nov
2020
So You Have a Cool Platform. The Next Decision Will Make or Break Your Company
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Sep
2020
What We Know About COVID-19, and What We Don’t
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Jul
2020
The Vintage of 2020: How COVID-19 is Molding Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
May
2020
The Recovery: A Long Road Ahead for Patients, Healthcare Workers, and Hospitals
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Apr
2020
Bridging the Social Divide in the Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2020
A Surge of Gratitude, From a Doctor on the Front Lines of COVID-19 in Boston
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2020
Life on the Front Lines of the COVID-19 Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Jan
2020
We’ve Been Neglecting Common Diseases. We Need to Reverse this Trend
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2019
Don’t Pull Back on Basic Biology for Psychiatry: It’s Time to Double Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Sep
2019
Dr. Jekyll and Mr. Pharma-Bro: Coping With My Split Personality
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2019
Just Because You Can Doesn’t Mean You Should: Gene Therapy is Not the Solution to Every Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2019
Investing from the Heart to Find New ALS Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Mar
2019
The Biotech Industry Can Help Address the Opioid Crisis. But We Aren’t Doing Enough
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jan
2019
Hurricane Lantus Is Changing the Drug Pricing Dynamic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.